Genmab — Oktober 2020
-
Måske lykkes det....inden uge 46.
-
Jeg sidder og fundere over om det ikke vil kræve exceptionelle gode nyheder i uge 46 for at den kommer op i 24-2500 igen?
-
Så er spørgsmålet vel om tiden er normal?
-
-
De lave renter vil medvirke kraftigt til at flere vil invester i aktier fremadrettet og her ser jeg genmab, novo, ørsted som nogle der kan stige en hel del mere de kommende år, måske enda næste 5-10år. Disse her korektioner eller retracements om man vil, på 10-15 %, kommer 4-5 gange per år så det ser sådanset stadig rimlig normalt ud efter min mening. Synes også der begynder at være tegn på bundvending for Genmabs vedkommende
-
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity (Camidanlumab ) https://jitc.bmj.com/content/8/2/e000860
-
Non-Chemotherapy Regimen Induces Encouraging Responses in Advanced EGFR-Mutant NSCLC (Amivantamab ) https://www.targetedonc.com/view/non-chemotherapy-regimen-induces-encouraging-responses-in-advanced-egfr-mutant-nsclc
-
Nice increase in (Anticipated) Enrollment: from 122 to 222 for innovaTV 208 https://clinicaltrials.gov/ct2/history/NCT03657043?A=25&B=26&C=merged#StudyPageTop
tvivler, Du tænker på hvis Sleepy Joe vinder valget ? Covid19 bør ikke presse Genmab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind